linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth

Get access to free reads

Start Your Trial Start Your membership

Get 15-day free trial to all of ET Prime

Start Your Trial Start Your membership
Not a member
Already a member?
Not a member

Your membership

RENEW
ET Prime

80% jump in 6 months, Covid vaccine can give this stock a shot in the arm

Opportunity to launch a vaccine would mean one-time exceptional business gain, brand boost
Increase Font
Decrease Font
Cancel
18 Sep 2020 1 Mins Read 0 comment
Sputnik V vaccine, if found efficacious, can prove to be quite beneficial for DRL. Agencies
Sputnik V vaccine, if found efficacious, can prove to be quite beneficial for DRL.
Mumbai: Drug major Dr Reddy’s Labs (DRL) is one Indian pharma company that has made all the right moves amid the pandemic with the latest being the tie-up with Russian Direct Investment Fund, a sovereign fund from Russia, for conducting clinical trials and distribution of the Sputnik V Covid vaccine in India. The Street cheered the company’s move, with
India launch is dependent on several factors like the conduct and protocol of clinical trials, results of the trials, time taken to seek regulatory approvals and pricing of the vaccine if it is cleared for commercialisation. Amidst this uncertainty, having an agreement to distribute 100 million doses may seem premature but is a step in the right direction for DRL.
Mumbai: Drug major Dr Reddy’s Labs (DRL) is one Indian pharma company that has made all the right moves amid the pandemic with the latest being the tie-up with Russian Direct Investment Fund, a sovereign fund from Russia, for conducting clinical trials and distribution of the Sputnik V Covid vaccine in India. The Street cheered the company’s move, with India launch is dependent on several factors like the conduct and protocol of clinical trials, results of the trials, time taken to seek regulatory approvals and pricing of the vaccine if it is cleared for commercialisation. Amidst this uncertainty, having an agreement to distribute 100 million doses may seem premature but is a step in the right direction for DRL.

The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.

Gift this story

YOU CAN GIFT 0 MORE STORIES THIS MONTH

Maximum 10 Email IDs allowed

300 characters remaining

Gift Sent Successfully

Limit Reached
Limit Reached

You’ve gifted all the 0 articles from your monthly gift bucket!

Please come back next month.

0 more articles will be waiting for you in your gift bucket.

Current Edition

[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]